REDUCE-IT

Study / Research

A study that tested 4 grams of EPA in people with heart disease or diabetes and elevated triglycerides, showing spectacular results in reducing cardiovascular events.

Mentioned in 3 videos

Videos Mentioning REDUCE-IT

#134 - James O’Keefe, M.D.: Preventing cardiovascular disease and the risk of too much exercise

#134 - James O’Keefe, M.D.: Preventing cardiovascular disease and the risk of too much exercise

Peter Attia MD

A study that tested 4 grams of EPA in people with heart disease or diabetes and elevated triglycerides, showing spectacular results in reducing cardiovascular events.

#129 - Tom Dayspring, M.D.: The latest insights into cardiovascular disease and lipidology

#129 - Tom Dayspring, M.D.: The latest insights into cardiovascular disease and lipidology

Peter Attia MD

A major clinical trial in which Amarin's branded EPA medication (Vascepa) at a high dose (4 grams/day) showed a nearly 30% reduction in residual cardiovascular risk in high-risk patients already on statins with elevated triglycerides.

#83 – Bill Harris, Ph.D.: Omega-3 fatty acids

#83 – Bill Harris, Ph.D.: Omega-3 fatty acids

Peter Attia MD

A landmark clinical trial that showed a 25% reduction in cardiovascular events over 5 years with 4 grams of pure EPA (Vascepa) daily in statin-treated patients with elevated triglycerides and other risk factors, with virtually no side effects.